November 16, 2014Open Access

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Key Points

Key points are not available for this paper at this time.

Abstract

Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who had metastatic melanoma without a BRAF mutation. (Funded by Bristol-Myers Squibb; CheckMate 066 ClinicalTrials.gov number, NCT01721772.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Robert et al. (Sun,) studied this question.

www.synapsesocial.com/papers/69d7883edb9d5e1bf4b8b45f — DOI: https://doi.org/10.1056/nejmoa1412082

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma· 2014 · 2,026 citations
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma· 2014 · 1,860 citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)· 2008 · 29,236 citations
Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.· 2014 · 116 citations

Authors

Caroline Robert

Georgina V. Long

Benjamin Brady

Journals

New England Journal of Medicine

Actions

Institutions

Inserm

Université Paris Cité

Heidelberg University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion